Translational Science 2012

Translational sciences can help increase not only the speed at which a drug reaches the clinic, but also the efficacy of the drug, the safety profile of that drug and the treatment population. Cambridge Healthtech Institute’s Eighth Annual Translational Science conference at the 2012 Molecular Med Tri-Con will bring scientists from academia, industry and government together to discuss the role of translational science in drug discovery and development. While remaining in the forefront of pharmaceutical development news, translational science has become an integral component of modern drug discovery, starting with target validation and continuing through post-market surveillance. The role of the translational scientist may vary from organization to organization, but the underlying need to better understand and utilize the knowledge from both clinical and pre-clinical endeavors is crucial to reducing pharmaceutical attrition. What is the impact of having a pharmacodynamic vs. a prognostic biomarker? Can you implement a translational approach in a drug-diagnostic co-development project? What is the modern role for in vivo models in translational science? Learn from the experts and contribute to the conversation by bringing your experience to the forefront through interactive roundtables, moderated panel discussions and networking breaks. Case studies (from both small molecule and biologics) will be presented with an emphasis on the role of translational science in the success or failure of the compound. What are the lessons learned from the successes? Learn how these results are already translating back to pre-clinical research for similar targets.

Who should attend: Translational scientists, executives, executive scientists, researchers, biomarker experts, and anyone interested in how translational science can benefit their pharmaceutical development.